source
- Lilly proposes up to $1 billion for Alzheimer’s candidate, while Bial drops Parkinson’s programOn June 9, 2026, Eli Lilly announced a potential licensing agreement for an Alzheimer’s disease candidate, offering an upfront payment of $10 million and the possibility of more than $1 billion bas…
- Gilead reports positive Phase 3 HIV results while Merck's Trodelvy fails in lung cancer trialGilead Sciences announced that its Phase 3 HIV trial met its primary efficacy endpoint, delivering a positive readout for the experimental therapy. In a separate study, Merck reported that its Pha…